IndustryCompany release

Liquidia's YUTREPIA sales hit $222.7M in Q3, but settlement charge pushes company to $236.3M loss

🇺🇸 Liquidia Corp (LQDA) · Tue 10 Nov 2026

Net product sales rose 31% quarter on quarter, yet a $389.7M charge for the October settlement with United Therapeutics drove a GAAP net loss.

Liquidia Corp reported third-quarter 2026 results on 10 November, with net product sales of $222.7M for YUTREPIA (treprostinil) inhalation powder. That is 31% higher than in the second quarter. Adjusted EBITDA for the period was $140.5M.

The company booked a $389.7M charge linked to the global settlement of all litigation with United Therapeutics, reached in October. The charge pushed Liquidia to a GAAP net loss of $236.3M for the quarter.

Liquidia also noted that YUTREPIA has received FDA Fast Track designation in SSc-RP. In addition, a Prior Approval Supplement is pending with the FDA to remove the PH-ILD indication from the product label. The source summary gives no further detail on the reasons for the change or the expected timing of a decision.

The company said 11 studies are ongoing or planned, including trials of L606. No other trial details were available in the material reviewed.

What it means for your team

  • Regulatory teams tracking inhaled treprostinil should watch the outcome of the pending Prior Approval Supplement, since it would change the YUTREPIA label by removing the PH-ILD indication.
  • The Fast Track designation in SSc-RP is a development-stage signal for the product, not an approval for that use.
  • Market-access teams should note that the October settlement ends all litigation between Liquidia and United Therapeutics, which removes a legal overhang, although the financial terms beyond the $389.7M charge are not detailed here.

Company's press release (SEC filing): Liquidia Corp ↗

Article written by VigiEye from the official source (Liquidia Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →